CA-IMPERVA
3.11.2022 13:02:06 CET | Business Wire | Press release
Imperva, Inc., (@Imperva) the cybersecurity leader whose mission is to help organizations protect their data and all paths to it, releases The State of Security Within eCommerce 2022 report, a 12-month analysis by Imperva Threat Research of cybersecurity threats targeting the retail industry. A range of automated threats -- from account takeover, credit card fraud, web scraping, API abuses, Grinch bots, and distributed denial of service (DDoS) attacks -- were a persistent challenge for the eCommerce industry, threatening online sales and customer satisfaction. The continued barrage of attacks on retailers’ websites, applications, and APIs throughout the calendar year, and during the peak holiday shopping season, is a continued business risk for the retail industry.
“The holiday shopping season is a critical period for the retail industry, and security threats could undermine retailers’ bottom line again in 2022,” says Lynn Marks, Senior Product Manager, Imperva. “This industry faces a variety of security risks, the majority of which are automated and operate around the clock. Retailers need a unified approach to stop these persistent attacks, one that focuses on the protection of data and is equipped to mitigate attacks quickly without disrupting shoppers.”
An Automated Adversary: Bad Bots & Online Fraud Plague Retail Sites
In the past 12 months, nearly 40% of traffic on retailers’ websites didn’t come from a human. Instead, it came from a bot, software applications controlled by operators that run automated tasks, often with malicious intent. In the retail industry, the infamous Grinch bot is notorious for inventory hoarding during the holiday shopping season, scooping up high-demand items and making it challenging for consumers to purchase gifts online.
Some of the key trends monitored by Imperva include:
- Of all the traffic on retailers’ websites, nearly one-quarter (23.7%) was attributed specifically to bad bots, malicious automation that contributes to online fraud. The proportion of advanced bots -- scripts that use the latest evasion techniques to mimic human behavior and avoid detection -- on retail sites grew over the prior year (from 23.4% to 31.1%). Advanced bots are a considerable challenge for organizations to stop without the right defenses in place.
- In 2021, bot-related attacks on retail sites grew 10% in October and grew another 34% in November, suggesting that bot operators increase their nefarious efforts around peak holiday shopping periods.
- Account takeover (ATO) is another form of online fraud in which cybercriminals attempt to compromise online accounts by using stolen passwords and usernames. In 2021, 64.1% of ATO attacks used an advanced bad bot. Of all login attempts on retail websites, 22.6% were malicious, nearly twice the volume that was recorded on sites across other industries. Attackers used leaked credentials 94.7% of the time in credential stuffing attacks targeting retailers, compared to 69.6% of the time in other industries.
API Abuses and Attacks Multiply, Creating New Challenges for Retailers
APIs are the invisible connective tissue that enable applications to share data and invoke digital services. Analysis by Imperva Threat Research finds that traffic from an API accounts for 41.6% of all traffic to online retailers’ sites and applications. Of that, 12% of traffic directs to endpoints, like a database, where personal data is stored (e.g. credentials, identification numbers, etc.). More concerning, 3 - 5% of API traffic is directed to undocumented or Shadow APIs, endpoints that security teams don’t know exist or no longer protect.
Exposed or vulnerable APIs are a considerable threat for retailers because attackers can use the API as a pathway for exfiltrating customer data and payment information. API abuses are often carried out through automated attacks where a botnet floods the API with unwanted traffic, seeking vulnerable applications and unprotected data. In 2021, API attacks increased by 35% between September and October, and then spiked another 22% in November on top of the previous months’ elevated attack levels. This finding suggests that bad actors scale their efforts around the holiday shopping season as more data is exchanged between the APIs and applications that power eCommerce services.
Beware of Downtime: DDoS Attacks Continue to Threaten Retailers
A distributed denial of service (DDoS) attack is an automated threat that attempts to disrupt critical business operations by flooding the network or application infrastructure with malicious traffic. The attacks are often launched by a botnet, a group of compromised connected devices that are distributed across the Internet and operated by a single party.
Imperva Threat Research finds that DDoS attacks in 2022 are larger and stronger across all industries. The number of incidents recorded that were greater than 100 Gbps doubled, and attacks larger than 500 Gbps/0.5 Tbps increased 287%. What’s more, those targeted by an attack are often attacked again within 24 hours. In fact, 55% of websites hit by an application layer DDoS and 80% hit by a network layer DDoS were attacked multiple times.
A DDoS attack is a nonstop threat for retailers. The downtime caused by a DDoS attack can lead to site disruption, reputational damage, and revenue loss. A DDoS is a critical threat to online retailers that rely on application performance and availability to enable digital storefronts.
Additional Information:
- Download the The State of Security Within e-Commerce 2022 report
- Learn how Imperva products and solutions help retailers protect their applications, APIs, and data from security risks.
- See how bad bots create business disruption across different industries.
- Check out the Imperva Blog for the latest product and solution news, and threat intelligence from Imperva Threat Research.
About Imperva:
Imperva is the comprehensive digital security leader on a mission to help organizations protect their data and all paths to it. Only Imperva protects all digital experiences, from business logic to APIs, microservices, and the data layer, and from vulnerable, legacy environments to cloud-first organizations. Customers around the world trust Imperva to protect their applications, data, and websites from cyber attacks. With an integrated approach combining edge, application security, and data security, Imperva protects companies ranging from cloud-native start-ups to global multi-nationals with hybrid infrastructure. Imperva Threat Research and our global intelligence community keep Imperva ahead of the threat landscape and seamlessly integrate the latest security, privacy, and compliance expertise into our solutions.
© 2022 Imperva, Inc. All rights reserved. Imperva is a registered trademark of Imperva, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
